NRP Epinephrine Dose, Route, and Administration

Epinephrine is the only drug recommended during neonatal resuscitation, and the Neonatal Resuscitation Program (NRP) specifies it for newborns whose heart rate remains below 60 beats per minute despite effective ventilation and chest compressions. The recommended intravenous or intraosseous dose is 0.01 to 0.03 mg/kg of a 1:10,000 concentration, while a higher endotracheal dose of 0.05 to 0.1 mg/kg can be given while vascular access is being established. Getting the drug into the bloodstream quickly, at the right dose, and through the right route turns out to be far more complex in a transitioning newborn than these brief guidelines might suggest.

When Epinephrine Enters the Picture

Epinephrine is not a first-line intervention. NRP’s structured algorithm prioritizes airway management, effective positive-pressure ventilation, and coordinated chest compressions before any medication is considered. In practice, only a small fraction of newborns ever need epinephrine. The drug is indicated when compressions and ventilation together fail to bring the heart rate above 60 bpm, a scenario that usually reflects severe perinatal asphyxia or profound circulatory collapse at birth.

The primary action of epinephrine in this context is to increase coronary perfusion pressure. During cardiac arrest, blood flow through the coronary arteries drops to almost nothing. Epinephrine’s alpha-adrenergic effects constrict peripheral blood vessels, redirecting what little blood the compressions generate toward the heart and brain. This is the mechanism that matters most for achieving return of spontaneous circulation (ROSC). However, the drug also stimulates beta-adrenergic receptors, which increases heart rate and the force of contractions but simultaneously raises the heart’s own oxygen demand. In a newborn already starved of oxygen, that increased demand is a genuine downside and one reason dosing precision matters.

IV and IO Dosing

The intravenous (IV) dose range for neonatal epinephrine is 0.01 to 0.03 mg/kg, drawn from a 1:10,000 solution. This range applies equally to the intraosseous (IO) route. In most delivery-room resuscitations, the IV route means an emergency umbilical venous catheter (UVC), threaded into the umbilical vein and advanced just far enough to get free blood flow. The dose may be repeated every three to five minutes if the heart rate stays below 60 bpm.

That three-fold range from 0.01 to 0.03 mg/kg has created real uncertainty for clinicians deciding what initial dose to draw up. Recent animal data suggests the higher end of the range is meaningfully more effective. In a lamb model of neonatal asphyxia, a dose of 0.03 mg/kg achieved ROSC about five times faster than 0.01 mg/kg when adjusting for flush volume.

This finding has pushed many experts to favor 0.02 or 0.03 mg/kg as the initial IV dose rather than starting at the low end, though the current guideline range technically permits either approach.

Why the Endotracheal Route Falls Short

Before vascular access is secured, some teams give the first dose of epinephrine down an endotracheal tube (ET) already placed for ventilation. The guideline dose for this route is higher, 0.05 to 0.1 mg/kg, precisely because drug absorption from the lungs is poor and unpredictable in a newborn whose lungs are fluid-filled and transitioning from fetal circulation.

Animal research has quantified just how unreliable this route is. In an ovine model comparing transitioning newborn lambs with postnatal lambs, peak blood levels of epinephrine after an ET dose were roughly a quarter of those seen in postnatal animals, and giving a second ET dose still failed to match what the postnatal group achieved with a single dose.

⁴

The fluid-filled, partially aerated lungs of a transitioning newborn simply do not absorb the drug the way mature, air-filled lungs do. This is not a subtle difference; it represents a several-fold reduction in the amount of epinephrine that actually reaches the bloodstream.

In another lamb study, the ET group took significantly longer to achieve ROSC compared with the IV group, with a median time of about 4.5 minutes versus 2 minutes. Many of the ET-only lambs eventually needed rescue IV epinephrine to achieve ROSC at all.

⁵

Human data paints a slightly more complex picture. A systematic review comparing IV and ET epinephrine in neonatal resuscitation found no statistically significant difference in death at hospital discharge between the two routes.

⁶

However, this finding comes with a major caveat: most infants who initially received ET epinephrine also went on to receive IV epinephrine afterward, making it difficult to isolate the effect of the ET dose alone. A national database review found that initial ET epinephrine was associated with a higher overall ROSC rate than initial IV epinephrine (about 70% versus 58%), but among those who received only one route, IV-only outperformed ET-only (roughly 58% versus 47%).

⁷

The interpretation here is that the ET dose may buy time and provide partial benefit while the team works to establish IV access, but it is not a reliable stand-alone replacement for vascular delivery.

The Saline Flush Makes a Bigger Difference Than You Might Expect

After pushing epinephrine through a UVC, you need a normal saline flush to clear the catheter dead space and move the drug into the central circulation. This step is easy to overlook or under-do during a high-stress resuscitation, but data from lamb studies shows it has a dramatic effect on drug delivery.

When researchers varied both the epinephrine dose and the flush volume, they found that a larger flush roughly tripled the speed of ROSC at the lower drug dose. At 0.01 mg/kg, plasma epinephrine levels were about six times higher one minute after dosing when a larger flush was used compared to a small flush.

The practical takeaway is that skimping on the flush can negate much of the benefit of the drug itself. NRP recommends following each IV dose with a 1 to 3 mL normal saline flush, but the evidence suggests that erring toward the higher end of that range matters, particularly when using the lower end of the dose range.

Vascular Access in the Delivery Room

The preferred vascular access point for neonatal resuscitation is the umbilical vein. The stump of the recently cut cord provides a relatively large vessel that can be cannulated without a peripheral IV attempt on a tiny, vasoconstricted newborn. In skilled hands, an emergency low-lying UVC can be placed reasonably quickly. But “skilled hands” is a variable. Umbilical catheterization is not something most clinicians practice frequently, and in simulation studies, the time and difficulty of UVC placement can be significant.

Intraosseous (IO) access has emerged as an important alternative. In a simulation comparing the two, IO needle placement was completed about 46 seconds faster than UVC insertion, with no significant difference in the number of errors.

⁸

Another model-based study found an even larger time gap, with IO access achieved in roughly 45 to 52 seconds compared with 95 to 134 seconds for UVC, and clinicians rated the IO procedure as easier on a difficulty scale.

⁸

Does the drug work as well through an IO needle as through a UVC? In asphyxiated newborn lambs, intraosseous epinephrine produced ROSC rates, plasma drug levels, and hemodynamic responses very similar to those seen with IV epinephrine.

⁹

Current NRP guidelines list IO as an acceptable alternative when UVC access is not quickly achievable, and many resuscitation experts consider it underutilized in the neonatal setting.

Why Intramuscular Injection Does Not Work in Newborns

Adults receiving epinephrine for anaphylaxis typically get an intramuscular (IM) injection, which might lead someone to wonder why the same approach is not used in neonatal arrest. The answer lies in the extreme hemodynamic compromise of an asphyxiated newborn. During cardiac arrest, blood flow to skeletal muscle is essentially absent, meaning a drug injected into muscle tissue just sits there.

This has been tested directly. In an asphyxiated lamb model, IM epinephrine produced no significant rise in plasma drug levels before ROSC. In a couple of animals, delayed absorption was seen several minutes after circulation was restored, but by that point the drug was no longer needed and could actually cause harm by producing unexpected blood pressure spikes.

¹⁰

The IM route is not recommended by any current neonatal resuscitation guideline, and the evidence firmly supports this exclusion.

Medication Errors Under Pressure

Neonatal epinephrine comes in a 1:10,000 concentration (0.1 mg/mL), and the volumes involved are tiny. For a 3 kg newborn at the standard IV dose, you are drawing up somewhere between 0.3 and 0.9 mL of fluid. These small volumes, prepared and administered in the chaos of a resuscitation, are vulnerable to error.

A simulation study found that the most common errors occurred during the drug-withdrawal and administration phases. About one in five administered doses had greater than 20% dosing error, and the largest percentage errors occurred when a large syringe was used to draw up or push a small volume of medication. The median time to prepare and deliver each dose was about 79 seconds.

¹¹

Using a syringe that is too large for the volume being measured means the graduations on the barrel are wider apart, making small inaccuracies in the plunger position translate into large percentage errors in the actual dose. The practical recommendation is to use a 1 mL syringe for neonatal epinephrine doses whenever possible and to have pre-drawn syringes or standardized kits available to reduce preparation time and variability.

Timing and Repeat Dosing

NRP guidelines recommend repeating epinephrine every three to five minutes if the heart rate remains below 60 bpm. The evidence base for this specific interval is thin, largely extrapolated from adult resuscitation data and expert consensus rather than neonatal-specific trials.

⁶

The urgency of timing extends beyond repeat dosing. Getting the first dose in quickly matters. In the lamb study comparing IV and ET routes, the IV group achieved ROSC in a median of 2 minutes, while the ET group (including those who eventually received rescue IV doses) took a median of 4.5 minutes.

⁵

Every minute of cardiac arrest in a newborn is a minute of compromised oxygen delivery to the brain and other organs. This time pressure is why teams often give an ET dose while simultaneously working to place a UVC, rather than waiting for vascular access to give any epinephrine at all. The ET dose is an imperfect bridge, but the alternative of further delay may be worse.

The Risks That Come After ROSC

Epinephrine does not simply restore heart function and disappear. Its beta-adrenergic effects increase the heart’s oxygen consumption at a time when the baby is recovering from a period of severe oxygen deprivation. This mismatch between oxygen supply and demand can worsen myocardial injury.

After ROSC, many newborns experience a period of systemic hypertension, sometimes described as an “overshoot.” In animal models, both IV and IO epinephrine produced a marked overshoot in blood pressure and carotid blood flow after circulation was restored.

⁹

For the fragile cerebral vasculature of a newborn, particularly a premature one, rapid swings in blood pressure can increase the risk of intraventricular hemorrhage. Additionally, respiratory and metabolic acidosis, which are nearly universal in neonates needing epinephrine, can blunt the hemodynamic response to the drug and aggravate the post-ROSC hypertension once pH begins to normalize.

The bottom line is that epinephrine is used because nothing else works as reliably to restart the heart, but it is not a benign drug, and minimizing both the time to administration and the total number of doses has real implications for the baby’s subsequent brain and heart health.

Vasopressin as an Alternative Agent

Researchers have explored whether vasopressin, a hormone that constricts blood vessels through a different receptor pathway, might offer advantages over epinephrine in neonatal resuscitation. Vasopressin acts primarily on V1 receptors in blood vessel walls, raising coronary perfusion pressure without the beta-adrenergic stimulation that increases myocardial oxygen demand.

In a piglet model of neonatal asphyxia, vasopressin and epinephrine achieved similar rates of ROSC and similar times to ROSC. The difference emerged in what happened afterward: piglets treated with vasopressin survived significantly longer in the post-resuscitation period, had better carotid blood flow immediately after ROSC, and showed improved heart rate, blood pressure, and cerebral oxygen saturation four hours later.

¹²

These results are intriguing because they suggest the beta-adrenergic “cost” of epinephrine, specifically the increased oxygen demand and exaggerated post-ROSC hemodynamic swings, might be avoidable with a different drug. However, this remains animal data from a single research group. Vasopressin is not recommended in any current neonatal resuscitation guideline, and human neonatal trials would be needed before it could enter clinical practice. Still, the finding highlights a real limitation of epinephrine that future guidelines may eventually address.

Where the Evidence Remains Weak

Much of what guides neonatal epinephrine use is extrapolated from adult cardiac arrest literature or derived from animal models. A systematic review cataloguing the evidence behind neonatal epinephrine’s dose, route, and interval found that the human data was sparse and largely observational, with no randomized controlled trials comparing different IV doses in human newborns.

⁶

This creates a situation where clinicians are making high-stakes decisions based on guidelines that their own authors acknowledge rest on limited evidence. The recommended dose range, the repeat interval, and even the preference for IV over ET are all reasonable inferences from what data exists, but none is backed by the kind of definitive human trial evidence that clinicians would prefer. Running randomized trials in this population is ethically and practically challenging: you cannot withhold a potentially lifesaving drug from a dying newborn, and the number of babies who need delivery-room epinephrine at any one institution is small enough that multi-center collaboration is essential.

What the animal data does offer is consistency. Across ovine and porcine models, the findings point in the same direction: higher IV doses work faster than lower ones, IV delivery outperforms ET delivery, adequate flush volume matters, IM injection does not work during arrest, and IO access is a viable alternative to UVC. These converging lines of evidence form a coherent picture even if the human-specific details remain to be filled in. For clinicians at the bedside, the practical guidance is reasonably clear even if the research underpinning it is not yet as strong as anyone would like.

1
Neonatology. Cardiac Agents during Neonatal Cardiopulmonary Resuscitation
2
PubMed Central. What is the optimal initial dose of epinephrine during neonatal resuscitation in the delivery room?
3
PubMed Central. Randomised trial of epinephrine dose and flush volume in term newborn lambs
4
PubMed Central. Bioavailability of endotracheal epinephrine in an ovine model of neonatal resuscitation
5
PubMed Central. Evaluation of Timing and Route of Epinephrine in a Neonatal Model of Asphyxial Arrest
6
Pediatrics. The Route, Dose, and Interval of Epinephrine for Neonatal Resuscitation: A Systematic Review
7
PubMed. Use of Initial Endotracheal Versus Intravenous Epinephrine During Neonatal Cardiopulmonary Resuscitation in the Delivery Room: Review of a National Database
8
Pediatrics. Comparison of Umbilical Venous and Intraosseous Access During Simulated Neonatal Resuscitation
9
Archives of Disease in Childhood: Fetal and Neonatal Edition. Comparison of intraosseous and intravenous epinephrine administration during resuscitation of asphyxiated newborn lambs
10
PubMed Central. Inadequate Bioavailability of Intramuscular Epinephrine in a Neonatal Asphyxia Model
11
BMJ Journals. Drug preparation and administration errors during simulated paediatric resuscitations
12
PubMed Central. Vasopressin versus epinephrine during neonatal cardiopulmonary resuscitation of asphyxiated post-transitional piglets